Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

What next for Sequenom? - a cautionary tale

This article was originally published in Clinica

Executive Summary

Allegations of falsification or misrepresentation of scientific data are not unknown in the healthcare industry, however, what has become public knowledge still can be characterised as “occasional”. Only a few days ago, Sanofi-Aventis was able to breathe a temporary sigh of relief as a federal judge dismissed a class action relating to possible increased suicidality linked to its anti-obesity drug rimonabant. Despite it having been withdrawn from the European market just months after its initial launch and not having been approved by the US FDA, the judge found that the defendants had failed to identify any specific safety data that were omitted from Sanofi-Aventis’ public disclosures.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT044434

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel